Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL-50 vs ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression. It also interacts with kappa and delta receptors to a lesser extent.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily in the CNS, reducing prostaglandin synthesis; analgesic and antipyretic. Oxycodone: mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.
Management of breakthrough pain in cancer patients (opioid-tolerant) (approved for transmucosal formulations),Anesthesia induction and maintenance (IV use),Premedication for anesthetic procedures,Off-label: Severe acute pain in emergency settings (e.g., procedural sedation),Off-label: Chronic pain management (transdermal patch only for opioid-tolerant patients)
Management of moderate to moderately severe pain,Acute pain,Chronic pain
50 mcg intravenously every 5-10 minutes as needed for breakthrough pain or for induction of anesthesia; for transdermal, 12-100 mcg/hour applied every 72 hours.
1-2 tablets (equivalent to 325-650 mg acetaminophen / 5-10 mg oxycodone) every 4-6 hours as needed for pain; maximum 12 tablets per day (acetaminophen limit 3900 mg/day or lower if hepatic risk).
Terminal elimination half-life: 3-12 hours (mean 7 hours); context: prolonged with continuous infusion or in elderly, hepatic impairment, or obesity due to accumulation in adipose tissue.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment or overdose); Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release); Clinical context: Terminal half-life of oxycodone may be prolonged in elderly or patients with renal/hepatic impairment.
Primarily metabolized via CYP3A4 in the liver to norfentanyl (inactive) and other metabolites; minor contributions from CYP3A5. Less than 10% excreted unchanged in urine.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP450 (CYP2E1, CYP3A4) to toxic NAPQI. Oxycodone: hepatic via CYP3A4 (major) and CYP2D6 (minor) to active metabolites (noroxycodone, oxymorphone).
Renal: 75% (primarily as metabolites, <10% unchanged); Fecal: 9%; Biliary: minor contribution.
Acetaminophen: renal excretion of metabolites (glucuronide 45-55%, sulfate 20-30%, cysteine and mercapturate conjugates 5-10%) and unchanged drug (<5%); Oxycodone: renal excretion of unchanged drug (approximately 10-19%) and metabolites (noroxycodone, oxymorphone, and their glucuronides) (total renal elimination ~60-87%); fecal elimination of Oxycodone is minimal (<10%).
80-85% bound, primarily to alpha-1-acid glycoprotein and albumin.
Acetaminophen: 20-30% (albumin); Oxycodone: 45-50% (albumin).
3-8 L/kg (mean 4 L/kg); high Vd indicates extensive distribution into tissues including skeletal muscle and fat.
Acetaminophen: 0.9-1.0 L/kg (suggests distribution into total body water); Oxycodone: 2.6-4.0 L/kg (suggests extensive tissue distribution).
IV: 100%; Transdermal: 92% (relative to IV, absolute bioavailability ~92%); Transmucosal (buccal, sublingual): 50-70%; Intranasal: 70-90%; Oral: low (<50% due to first-pass metabolism).
Acetaminophen: Oral 85-90%; Oxycodone: Oral 60-87% (first-pass metabolism), Rectal (oxycodone suppository) ~60-80%.
GFR 30-60 m L/min: reduce dose by 25-50%; GFR <30 m L/min: avoid or reduce dose by 50-75% and monitor closely.
e GFR 30-60 m L/min: start with 50% of usual dose, increase cautiously; e GFR <30 m L/min: start with 25% of usual dose, extend dosing interval to every 8-12 hours; avoid in dialysis due to oxycodone accumulation.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75% or avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: start with 50% of usual dose, maximum acetaminophen 2000 mg/day; Child-Pugh C: contraindicated.
Intravenous: 0.5-2 mcg/kg per dose every 5-10 minutes as needed; transdermal: not recommended for children under 2 years; for children >2 years, start at 12 mcg/hour based on prior opioid exposure.
Weight-based: oxycodone 0.05-0.15 mg/kg/dose (max 5 mg/dose) with acetaminophen 10-15 mg/kg/dose every 4-6 hours; maximum acetaminophen 75 mg/kg/day (not to exceed 4000 mg/day).
Starting dose should be 50-75% lower than in younger adults; titrate slowly; transdermal patch starting dose no higher than 25 mcg/hour; monitor for respiratory depression and cognitive impairment.
Start with lowest dose (e.g., half of adult dose), titrate slowly; avoid in patients with impaired renal/hepatic function or those at risk for falls; monitor for respiratory depression and constipation.
Black Box Warning: Risk of respiratory depression, addiction, abuse, and misuse; life-threatening respiratory depression and death can occur at any dose, especially with initial use or dose escalation. Concomitant use with CNS depressants (e.g., benzodiazepines, alcohol) may cause profound sedation, respiratory depression, coma, and death. Accidental exposure (especially in children) can be fatal.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen may cause hepatotoxicity; neonatal opioid withdrawal syndrome; CYP3A4 interaction with benzodiazepines or other CNS depressants.
Risk of respiratory depression requires monitoring; use with caution in COPD, decreased respiratory reserve, or hypoxia,Serotonin syndrome risk with concomitant serotonergic drugs,Adrenal insufficiency and androgen deficiency with prolonged use,Neonatal opioid withdrawal syndrome with prolonged maternal use during pregnancy,Severe hypotension, especially in hypovolemic patients,QT prolongation (high doses, especially IV),Risks of tolerance, physical dependence, and withdrawal upon abrupt discontinuation
Addiction, abuse, misuse; respiratory depression; accidental exposure; neonatal opioid withdrawal syndrome; hepatotoxicity (acetaminophen); interactions with CNS depressants; elderly or debilitated patients; renal impairment; severe hypotension; adrenal insufficiency; use in patients with head injury.
Hypersensitivity to fentanyl or any component,Acute or severe bronchial asthma in unmonitored settings,Significant respiratory depression (without resuscitative equipment),Paralytic ileus or known gastrointestinal obstruction,Concurrent use with MAOIs (within 14 days) for immediate-release forms (dose adjustment may be considered for transdermal under strict monitoring)
Hypersensitivity to acetaminophen or oxycodone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction (e.g., paralytic ileus); severe hepatic impairment; concurrent use with MAOIs or within 14 days.
Avoid alcohol; concurrent use increases risk of CNS depression and respiratory arrest. No specific food interactions; maintain usual diet. Grapefruit juice may slightly increase fentanyl levels via CYP3A4 inhibition but clinical significance is minimal with transdermal route.
Avoid alcohol. Grapefruit juice may increase oxycodone levels; limit or avoid grapefruit products. High-fat meals may delay absorption of oxycodone. Maintain adequate hydration to prevent constipation.
First trimester: Limited data, but animal studies show no structural teratogenicity at clinically relevant doses. Second/third trimester: Chronic exposure may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery. Avoid prolonged use.
Acetaminophen: Generally considered low risk; no consistent association with major malformations. Oxycodone: First trimester: No increased risk of major malformations in human studies. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use; respiratory depression at delivery. No specific human data for combination; extrapolated from individual components.
Fentanyl is excreted in breast milk in low amounts (M/P ratio ~0.4-0.5). Single doses are unlikely to harm infant, but chronic use may cause sedation or respiratory depression in the neonate. Monitor for drowsiness, poor feeding. Benefit-risk assessment recommended.
Acetaminophen: Compatible; M/P ratio ~1.0 (low transfer). Oxycodone: Low levels in milk; M/P ratio ~3.6 (relative infant dose 1.7–6.3% of maternal weight-adjusted dose). Monitor infant for drowsiness, respiratory depression. Use lowest effective dose, shortest duration.
Pregnancy may increase clearance of fentanyl due to expanded plasma volume and enhanced hepatic metabolism. Higher doses may be required for adequate analgesia, especially in the third trimester. Postpartum dose reduction may be needed. Individualize based on response and adverse effects.
Acetaminophen: No dose adjustment needed; use lowest effective dose. Oxycodone: Pharmacokinetic changes in pregnancy include increased clearance (due to enhanced hepatic metabolism and renal blood flow) and increased volume of distribution, potentially reducing plasma concentrations. Dose may need to be increased (monitor for efficacy and avoid withdrawal); however, use lowest effective dose to minimize neonatal risks. Consider non-opioid alternatives.
Fentanyl 50 mcg/hr patch provides continuous systemic opioid delivery. Onset of action 12-24 hours; steady state in 72 hours. Do not cut or use damaged patches. Avoid heat sources (fever, heating pads, saunas) as they increase absorption and risk of overdose. Monitor for respiratory depression, especially in opioid-naïve patients. C max may increase by 25-40% with fever. Apply to non-irritated, non-hairy skin on upper torso. Use in opioid-tolerant patients only.
Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen intake should not exceed 4000 mg. Oxycodone has high abuse potential; consider prescribing naloxone for patients at risk of opioid overdose. Avoid concurrent use of other CNS depressants. Use with caution in elderly or renally impaired patients.
Apply patch to clean, dry, hairless skin on chest or back, avoiding scars, lesions, or irritated skin.,Do not cut, tear, or alter the patch in any way; this can cause rapid, fatal drug absorption.,Wash hands after applying or removing patch; avoid touching eyes or mucous membranes.,Keep away from children and pets; used patches should be folded, placed in original packaging, and disposed of per local drug take-back programs.,Avoid hot tubs, saunas, electric blankets, heating pads, or prolonged sun exposure while wearing patch; fever can increase absorption.,Do not drink alcohol while using fentanyl; it can cause severe drowsiness, respiratory depression, and death.,Common side effects include nausea, constipation, drowsiness, and dizziness. Contact healthcare provider if you experience confusion, slow or shallow breathing, or severe sedation.
Do not exceed 4000 mg of acetaminophen per day from all sources.,This medication can cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol while taking this medication.,Take exactly as prescribed; do not crush, chew, or break extended-release tablets.,Store securely out of reach of children and dispose of unused medication properly.,Seek emergency medical attention if you experience difficulty breathing, severe drowsiness, or signs of an allergic reaction.
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTANYL-50 vs ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE, answered by our medical review team.
FENTANYL-50 is a Opioid Agonist that works by Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression. It also interacts with kappa and delta receptors to a lesser extent.. ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily in the CNS, reducing prostaglandin synthesis; analgesic and antipyretic. Oxycodone: mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL-50 and ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL-50 is: 50 mcg intravenously every 5-10 minutes as needed for breakthrough pain or for induction of anesthesia; for transdermal, 12-100 mcg/hour applied every 72 hours.. The standard adult dose of ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is: 1-2 tablets (equivalent to 325-650 mg acetaminophen / 5-10 mg oxycodone) every 4-6 hours as needed for pain; maximum 12 tablets per day (acetaminophen limit 3900 mg/day or lower if hepatic risk).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FENTANYL-50 and ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE. The risk or severity of adverse effects can be increased when Oxycodone is combined with Fentanyl. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FENTANYL-50 is classified as Category D/X. First trimester: Limited data, but animal studies show no structural teratogenicity at clinically relevant doses. Second/third trimester: Chronic exposure may cause neonatal opioid. ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent association with major malformations. Oxycodone: First trimester: No increased risk of major malformations in human stud. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.